Insider Selling: Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Sells $36,000.00 in Stock

Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Rhonda Farnum sold 4,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $9.00, for a total transaction of $36,000.00. Following the sale, the senior vice president now directly owns 309,565 shares of the company’s stock, valued at approximately $2,786,085. This trade represents a 1.28 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Rhonda Farnum also recently made the following trade(s):

• On Monday, November 11th, Rhonda Farnum sold 4,000 shares of Theravance Biopharma stock. The shares were sold at an average price of $9.00, for a total transaction of $36,000.00.

Theravance Biopharma Stock Up 8.3 %

NASDAQ:TBPH opened at $10.47 on Friday. Theravance Biopharma, Inc. has a 12-month low of $7.44 and a 12-month high of $10.90. The stock’s fifty day simple moving average is $9.47 and its 200-day simple moving average is $8.92. The firm has a market capitalization of $514.85 million, a P/E ratio of -10.37 and a beta of 0.21.

Theravance Biopharma (NASDAQ:TBPH) last issued its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.16). The company had revenue of $16.87 million for the quarter, compared to the consensus estimate of $16.11 million. Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%. During the same quarter last year, the business posted ($0.17) EPS. As a group, equities research analysts expect that Theravance Biopharma, Inc. will post -1.09 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of TBPH. American Century Companies Inc. boosted its position in shares of Theravance Biopharma by 11.7% during the second quarter. American Century Companies Inc. now owns 57,611 shares of the biopharmaceutical company’s stock worth $489,000 after purchasing an additional 6,026 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of Theravance Biopharma by 38.4% during the second quarter. Dimensional Fund Advisors LP now owns 330,181 shares of the biopharmaceutical company’s stock worth $2,800,000 after purchasing an additional 91,679 shares during the period. Hsbc Holdings PLC bought a new position in shares of Theravance Biopharma during the 2nd quarter valued at about $108,000. XTX Topco Ltd bought a new position in Theravance Biopharma in the second quarter valued at approximately $129,000. Finally, Bank of Montreal Can increased its position in shares of Theravance Biopharma by 141.0% during the second quarter. Bank of Montreal Can now owns 160,138 shares of the biopharmaceutical company’s stock worth $1,414,000 after acquiring an additional 93,702 shares in the last quarter. Institutional investors and hedge funds own 99.10% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.